NMPA Issued the Announcement on the Guidelines for Real-World Evidence to Support Drug Development and Review (Interim)

2020-01-07

NMPA has organized the formulation of the Guidelines for Real-World Evidence to Support Drug Development and Review (Interim).

NMPA Issued the Announcement on Revising the Package Inserts of Prescription and Over-the-counter Oral Preparations such as Huoxuezhitong Capsules

2019-11-08

NMPA Released Announcement on the Application of 15 ICH Guidelines Including E1: Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions

2019-11-12

On November 12, 2019, NMPA issued the Announcement on the Application of 15 ICH Guidelines Including E1: Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life-Threatening Conditions.

NMPA Released Announcement on the Application of 13 ICH Guidelines Including S1A: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals

2019-11-12

On November 12, 2019, NMPA issued the Announcement on the Application of 13 ICH Guidelines Including S1A: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals.

NMPA Issued Announcement on Five Supplementary Test Methods Including Testing Items for Abietic Acid in Chenxianghuazhi Pills

2019-11-26

CPC Central Committee and the State Council Issued Opinions on Facilitating the Inheritance, Innovation and Development of Traditional Chinese Medicine

2019-10-29

Recently, the Central Committee of the Communist Party of China and the State Council issued the Opinions on Facilitating the Inheritance, Innovation and Development of Traditional Chinese Medicine (hereinafter referred to as Opinions), proffering 20 suggestions from 6 aspects.